PF-03654746
- Generic Name
- PF-03654746
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24F2N2O
- CAS Number
- 935840-31-6
- Unique Ingredient Identifier
- G3QE979K1X
- Background
PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01475383
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Manhasset, New York, United States
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01028911
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Wichita, Kansas, United States
A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 95
- Registration Number
- NCT01006122
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Houston, Texas, United States
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00562120
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Omaha, Nebraska, United States
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00531752
- Locations
- ๐บ๐ธ
Bay Area Research Institute, Lafayette, California, United States
๐บ๐ธPharmacology Research Institute, Newport Beach, California, United States
๐บ๐ธNew York University School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath